ORIGINAL ARTICLE
Predictive value of ALDH1 and CD44 positivity for radiotherapy response and prognosis in early-stage glottic laryngeal squamous cell carcinoma
1
Department of Otorhinolaryngology, Faculty of Medicine, Cukurova University, Adana, Turkey
2
Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey
Submission date: 2021-12-23
Acceptance date: 2022-02-05
Publication date: 2022-06-29
Pol J Pathol 2022;73(1):43-49
KEYWORDS
TOPICS
ABSTRACT
To evaluate the predictive value of CD44 and aldehyde dehydrogenase 1 (ALDH1) expression for prognosis and radiotherapy (RT) response in patients with early-stage laryngeal cancer receiving RT.
Forty-four patients with early-stage laryngeal cancer diagnosed between 2002 and 2016 were included in the study. The correlation between RT response and pre-treatment immunohistochemical ALDH1 and CD44 staining was evaluated. In addition, survival times were compared between groups.
The mean age of the 44 patients was 59.8 ±9.0 (43-81) years and 41 were male. There were 20 patients in the non-recurrent group (all men) and 24 patients in the recurrent group (21 men). Immunohistochemical positivity for ALDH1 was found to be a significant risk factor for RT failure (p = 0.0001), whereas CD44 positivity (p = 0.114) and age group (p = 0.287) were not significant.
ALDH1 positivity was identified as a significant predictor of DFS and RT sensitivity, while CD44 positivity did not differ according to RT response.
Forty-four patients with early-stage laryngeal cancer diagnosed between 2002 and 2016 were included in the study. The correlation between RT response and pre-treatment immunohistochemical ALDH1 and CD44 staining was evaluated. In addition, survival times were compared between groups.
The mean age of the 44 patients was 59.8 ±9.0 (43-81) years and 41 were male. There were 20 patients in the non-recurrent group (all men) and 24 patients in the recurrent group (21 men). Immunohistochemical positivity for ALDH1 was found to be a significant risk factor for RT failure (p = 0.0001), whereas CD44 positivity (p = 0.114) and age group (p = 0.287) were not significant.
ALDH1 positivity was identified as a significant predictor of DFS and RT sensitivity, while CD44 positivity did not differ according to RT response.
REFERENCES (39)
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA. Canc J Clinician 2012; 62: 10-29.
2.
Kokko LL, Hurme S, Maula SM, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 510-516.
3.
Institute NC. Cancer Stat Facts: Larynx Cancer Surveillance, Epidemiology, and Results (SEER) database. 2016.
4.
Wolf GT, Fisher SG, Hong WK, et al. Induction chemotherapy plus radiation comparedd with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
5.
Ries LA, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975-2003. National Cancer Institute, Bethesda 2006.
6.
Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19: 4029-4036.
7.
Karatzanis AD, Psychogios G, Zenk J, et al. Comparison among different available surgical approaches in T1 glottic cancer. Laryngoscope 2009; 119: 1704-1708.
8.
Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266: 1333-1352.
9.
Yoo J, Lacchetti C, Hammond JA, Gilbert RW; Head and Neck Cancer Disease Site Group. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the managementt of early (T1) glottic cancer: a systematic review. Head Neck 2014; 36: 1807-19.
10.
Mendenhall WM, Werning JW, Hinerman RW, et al. Management of T1-T2 glottic carcinomas. Cancer 2004; 100: 1786-92.8.
11.
Abdurehim Y, Hua Z, Yasin Y, et al. Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head Neck 2012; 34: 23-33.
12.
Wiernik G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991; 19: 411-417.
13.
Westerbeek HA, Mooi WJ, Hilgers FJ, et al. Ploidy status and the response of T1 glottic carcinoma to radiotherapy. Clin Otolaryngol 1993; 18: 98-101.
14.
Gallo O, Libonati GA, Gallina E, et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991; 117: 1007-1010.
15.
Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Ann Rev Dev Biol 2007; 23: 675-699.
16.
Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Canc 2010; 103: 439-445.
17.
Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Canc Res: Offic J Am Assoc Canc Res 2008; 14: 4085-4095.
18.
Yu CC, Chang YC. Enhancement of cancer stem-like and epithelial mesenchymal transdifferentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. Toxicol Appl Pharmacol 2013; 266: 459-469.
19.
Chen YS, Wu MJ, Huang CY, et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PloS One 2011; 6: e28053.
20.
Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol Targets Ther 2012; 6: 379-383.
21.
Joshua B, Kaplan MJ, Doweck I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 2012; 34: 42-49.
22.
Chikamatsu K, Takahashi G, Sakakura K, et al. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 2011; 33: 208-215.
23.
Amin M, Edge S, Greene F, et al. AJCC cancer staging manual. 8th ed. Springer, New York 2017.
24.
Baird BJ, Sung CK, Beadle BM, Divi V. Treatment of early-stage laryngeal cancer: a comparison of treatment options. Oral Oncol 2018; 87: 8-16.
25.
Warner L, Chudasama J, Kelly CG, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev 2014; 2014: CD002027.
26.
Obid R, Redlich M, Tomeh C. The treatment of laryngeal cancer. Oral Maxillofac Surg Clin North Am 2019; 31: 1-11.
27.
Mucha-Małecka A, Małecki K, Amrogowicz N, et al. Prognostic factors in elderly patients with T1 glottic cancer treated with radiotherapy. Sci Rep 2021; 11: 17717.
28.
Murakami N, Mori T, Yoshimoto S, et al. Expression of EpCAM and prognosis in early-stage glottic cancer treated by radiotherapy. Laryngoscope 2014; 124: 431-436.
29.
Schrijvers ML, van der Laan BF, de Bock GH, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 161-169.
30.
Zhang S, Hayashi R, Fujii M, et al. Total microvessel perimeter per tumor area is a predictor of radiosensitivity in early-stage glottic carcinoma. Int J Radiat Oncol Biol Phys 2009; 73: 1104-1109.
31.
Noordhuis MG, Kop EA, Bert van der Vegt, et al. Biological tumor markers associated with local control after primary radiotherapy in laryngeal cancer: a systematic review. Clin Otolaryngol 2020; 45: 486-494.
32.
Fang L, Shi L, Wang W, et al. Low expression of CIP4 in predicting worse overall survival: a potential biomarker for laryngeal cancer. PLoS One 2021; 16: e0253545.
33.
Chen C, Wei Y, Hummel M, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011; 6: e16466.
34.
Greco N, Schott T, Mu X, et al. ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther 2014; 5: 331-338.
35.
Chen YC, Chen YW, Hsu HS, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009; 385: 307-313.
36.
Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S a 2007; 104: 97973-97978.
37.
Al-Assar O, Muschel RJ, Mantoni TS, et al. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009; 75: 1216-1225.
38.
Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. Oral Oncol 2014; 50: 1144-1148.
39.
Lopez-Gonzalez A, Salas C, Provencio M, et al. Aldehyde dehydrogenases in early stage lung cancer: nuclear expression. Clin Transl Oncol 2014; 16: 931-934.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
